-+ 0.00%
-+ 0.00%
-+ 0.00%

Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham

Reuters·03/26/2026 10:02:50

Please log in to view news